Salix Pharmaceuticals, Ltd. news

   Watch this stock
Showing stories 1 - 10 of about 98   

Articles published

SLXP 144.50 +5.14 (3.69%)
price chart
Why Salix Pharmaceuticals (SLXP) Stock Is Surging Today
NEW YORK (TheStreet) -- Shares of Salix Pharmaceuticals Ltd. (SLXP) are up 3.71% to $156.70 in pre-market trade after it was reported that the company is in talks to sell itself to Actavis Plc, (ACT) , sources told Bloomberg, after it failed to reach a ...
Salix Pharmaceuticals, Ltd. (Nasdaq: SLXP) to Ring The Nasdaq Stock Market ...  GlobeNewswire (press release)
Salix Pharma scuttles Cosmo Technologies merger  U.S. News & World Report
Related articles »  
RSI Alert: Salix Pharmaceuticals (SLXP) Now Oversold
In trading on Monday, shares of Salix Pharmaceuticals Ltd (NASD: SLXP) entered into oversold territory, hitting an RSI reading of 29.0, after changing hands as low as $135.60 per share.
Related articles »  
Stifel Raises Price Target On Salix Pharmaceuticals, Ltd. On Possible Takeover
Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) received a price target increase from $155 to $185 by Stifel, which maintained a Buy rating.
Salix Pharmaceuticals Price Target Raised to $185.00 (SLXP)  Ticker Report
Stifel Nicolaus Increases Salix Pharmaceuticals Price Target to $185.00 (SLXP)  Watch List News (press release)
Related articles »  
Salix's Xifaxan Sales Expected To Go Downhill
Sales of Salix Pharmaceuticals, Ltd.'s (SLXP) drug Xifaxan face the risk of decline due to availability of new all-oral drugs for treatment of the hepatitis C virus (HCV), according to physician survey along with research conducted by Credit Suisse ...
Pharma Stocks in the News: Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP ...
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) said it has received final Food and Drug Administration approval for its Uceris rectal foam product to induce remission in patients with active mild-to-moderate distal ulcerative colitis.
Related articles »  
A Bizarre Pharma Love Triangle
Salix Pharmaceuticals is a specialty pharma company that specializes in gastroenterology treatments. In the article, I mentioned Salix Pharmaceuticals was being discussed as a prime candidate to do a tax-inversion deal. Just a few days later on July ...
Salix Said in Talks to Sell to Actavis as Allergan Fades  Bloomberg
Shareholder T. Rowe Price urges Allergan to hold off on deals  Reuters
Related articles »  
Sell Side's Views On Salix-Actavis Potential Merger
Allergan, in a desperate attempt to fend off Valeant's bid, revived acquisition talks with another pharmaceutical company, Salix Pharmaceuticals, Ltd. (SLXP), in September. Allergan believes that acquisition of Salix would make Allergan a complex and ...
Salix: The Field of Potential Buyers is Vast, Analyst Says  Wall Street Journal (blog)
Exclusive: Actavis plans new merger approach for Allergan - sources  Reuters India
Related articles »  
Salix Pharmaceuticals Announces 3Q2014 Financial Results Conference Call ...
RALEIGH, N.C., Oct 23, 2014 (BUSINESS WIRE) -- Salix Pharmaceuticals, Ltd. SLXP, -1.73% today announced that the Company will report third quarter 2014 financial results following the close of the U.S.
Stocks in the News � Atmel, (NASDAQ:ATML), Salix Pharmaceuticals, (NASDAQ ...  Techsonian (press release)
Related articles »  
Salix Pharmaceuticals Outlines Data Presentations at American College of ...
RALEIGH, N.C. - Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that presentations related to research of two of the Company's products are scheduled to take place during the American College of Gastroenterology (ACG) 2014 Annual ...
Related articles »  
EC approves ulcerative colitis med
The European Commission approves privately-held Switzerland-based Ferring Pharmaceuticals' Cortiment (budesonide) for the induction of remission in patients with active mild-to-moderate ulcerative colitis.
Ferring Pharmaceuticals: CORTIMENT � MMX� , a new treatment for ulcerative ...  Business Wire (press release)
Related articles »